- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
iCeutica, Inc. announces nano-pharmaceuticals industry leader Dr. William Bosch has joined iCeutica, Inc. Until recently, Dr. Bosch was a senior member of the research and development management team at Elan Corporation responsible for Elan's NanoCrystal® Technology and the related drug reformulation and delivery business.
Dr. Bosch brings more than fifteen years of scientific innovation, leadership and team-building experience in pharmaceutical product development and drug delivery, having been a co-inventor, or having played a key role in the development of four of the five nano-particulate based drugs approved by the FDA in the last decade. His roles at Elan have encompassed basic research into nano-pharmaceuticals production, formulation science, regulatory strategy and IP prosecution. Dr. Bosch is widely regarded as a leader in the fields of drug delivery and manufacturing of nano-particles for pharmaceutical applications.
Dr. Bosch joins the team which is advancing a number of reformulated products into the clinic, utilizing iCeutica's proprietary Encapsulated Organic Nanoparticle (EON™) Platform. In addition to iCeutica's pipeline, these products include drugs reformulated under the recent collaboration with Iroko Pharmaceuticals as well as those being developed by Spree Pharma A/S, an iCeutica joint venture company.
"We are very pleased to have Dr. Bosch join us at this exciting period of the Company's growth. We are in the process of scaling up the EON platform in preparation for clinical trials and commercial manufacturing. Dr Bosch's unrivalled experience with nano-reformulation technologies will provide a significant boost to our regulatory and customer engagements," stated iCeutica CEO, Matt Callahan.
"iCeutica's EON platform is broadly applicable to a wide range of poorly soluble drug compounds and provides a novel and exciting approach to drug formulation development and drug product manufacturing. I am delighted to be joining the iCeutica team and look forward to working with them and our partners to maximize the potential of this important new technology," said Dr. Bosch.
About iCeutica, Inc.
iCeutica commercializes products developed utilizing its proprietary EON™ Platform. EON is an enabling reformulation technology which applies simple and scalable processes to reformulate development stage and marketed products with solubility, delivery or bioavailability challenges.
For more information, please click here
Lisa Gray, EVP Corporate Development
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016